One switch raised questions, but by the time the COVID-19 vaccine reached commercial scale, the changes were considered minor.

The US biotech major has unveiled plans to open a new research and manufacturing center in the UK, which signals the start of detailed talks with the government about establishing a long-term partnership.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

After returning to the neuroscience space in the summer through a big-money deal with Alector, GlaxoSmithKline is setting up an institute with the University of Oxford that will target neurological diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, frontal temporal dementia, ALS and pain.